Merck & Co Inc
NYSE:MRK
Products
Keytruda (Pembrolizumab) Plus Lenvima (Lenvatinib) Combination Demonstrated Statistically Significant Improvement In Overall Survival
Published: 12/16/2020 11:55 GMT
Merck & Co Inc (MRK) - Keytruda® (pembrolizumab) Plus Lenvima® (lenvatinib) Combination Demonstrated Statistically Significant Improvement in Overall Survival, Progression-free Survival and Objective Response Rate Versus Chemotherapy in Patients With Advanced.
.
Merck & Co Inc - Phase 3 Keynote-775/study 309 Trial Evaluating Investigational Use of Keytruda Plus Lenvima Met Dual Primary Endpoints.
Merck & Co Inc - Trial Evaluating Investigational Use of Keytruda Plus Lenvima Met Its Secondary Efficacy Endpoint of Objective Response Rate.
Merck & Co Inc - Safety Profile of Keytruda Plus Lenvima Combination in Study Was Consistent With Previously Reported Studies.
.
Merck & Co Inc - Phase 3 Keynote-775/study 309 Trial Evaluating Investigational Use of Keytruda Plus Lenvima Met Dual Primary Endpoints.
Merck & Co Inc - Trial Evaluating Investigational Use of Keytruda Plus Lenvima Met Its Secondary Efficacy Endpoint of Objective Response Rate.
Merck & Co Inc - Safety Profile of Keytruda Plus Lenvima Combination in Study Was Consistent With Previously Reported Studies.